Denali Therapeutics (DNLI) Gains from Sales and Divestitures (2017 - 2018)
Denali Therapeutics (DNLI) reported Gains from Sales and Divestitures of $200000.0 for Q1 2018, down 60.0% year-over-year from $500000.0 in Q1 2017, and down 60.0% on a QoQ basis from $500000.0 in Q1 2017.
Denali Therapeutics (DNLI) has 2 years of Gains from Sales and Divestitures data on file, last reported at $200000.0 in Q1 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Denali Therapeutics | 3.82 Bn | 3.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2018 | 200,000.00 |
| Mar 31, 2018 | 200,000.00 |
| Mar 31, 2017 | 500,000.00 |
| Mar 31, 2017 | 500,000.00 |